

# INDEX

## A

Adhesion assays ..... 211, 213, 214  
Anti-Androgens ..... 259  
Androgen receptor (AR)  
  coactivators ..... 219, 221, 259, 260  
  target gene expression ..... 118, 119, 122–126  
Annexin V assays ..... 158, 160, 165, 166  
Apoptosis ..... 44, 155–160, 162–165, 178, 260

## B

Biobanking ..... 238–243  
Bioluminescence imaging ..... 84, 85, 87, 89–95, 97, 98, 100  
Biopsy ..... 21, 56, 109, 153, 239, 242,  
  243, 248, 253  
Breast cancer ..... 175–192

## C

Caspases ..... 41, 156, 158, 159  
cDNA synthesis ..... 122–124  
Cell culture  
  epithelial ..... 65, 147, 176  
  stromal, 60, 65, 176  
Cell culture medium ..... 72, 73, 199, 240  
Cell line derivation ..... 220  
Cell ploidy assays ..... 162, 163, 169  
Chemotherapy resistance ..... 158, 170  
Chromatin immunoprecipitation (ChIP) ..... 126–130,  
  220–226  
Coactivators ..... 219, 221, 259–262  
Colony forming assays ..... 65  
Corepressors ..... 220  
Cre *lox P* system ..... 196–199  
Cytoskeletal proteins ..... 68

## D

3D-ECMs ..... 212–214

## E

Endothelial and vascular cells ..... 30, 31  
Epithelial to mesenchymal transition (EMT) ..... 68  
ERG ..... 41, 44, 63, 107, 131

## F

Feeder cells ..... 56, 57, 60, 65  
Flow cytometry ..... 31, 135, 141–143, 145, 158, 162, 168, 169  
Fluorescence imaging ..... 84, 85, 87, 93

## G

Gelatin ..... 32, 34, 39, 40, 48, 175, 184, 185,  
  190–191, 209, 211, 212  
Gene fusions ..... 107, 131, 132, 134, 136  
Gene set enrichment analysis (GSEA) ..... 220, 227–231,  
  233, 234  
Gene silencing ..... 119  
Genotyping ..... 107, 108, 132, 133, 138, 144, 197–198,  
  200–202, 205  
Gleasons score ..... 30, 114, 153, 154

## H

Heat map ..... 233  
Hydrogels ..... 175, 184, 185, 190–191, 209, 211, 212, 215  
Hypoxia ..... 31, 35, 47–49, 177

## I

In situ hybridization ..... 104, 109, 158, 162, 163  
Intra-tibial injection ..... 15–16

## L

Laboratory animals imaging ..... 84, 85

## M

Matrigel ..... 63, 72, 73, 76, 86, 89, 136, 146–149,  
  176–178, 199, 215, 260, 261  
Metabolite pathway analysis ..... 237  
Metabolite quantification ..... 251, 252  
Metabolomics ..... 237–255  
Mitotic arrest ..... 155, 156, 158

## N

Nuclear magnetic resonance spectroscopy  
  (NMR) ..... 238, 243, 245, 247, 249–251, 253, 254  
Nuclear receptors (NRs) ..... 117, 220

**O**

Organoid culture ..... 136, 146–149, 199  
Overexpression ..... 119, 120, 132, 146,  
158, 204

**P**

P300/CBP coregulators ..... 260  
Patient-derived xenograft (PDX) ..... 1–24, 177  
PCR ..... 32, 50–51, 122–126, 130, 197–202, 221,  
223, 226, 227  
Pioneering factors ..... 220, 221  
Preclinical drug testing ..... 13, 18, 23  
Proliferation ..... 30, 44, 72, 76, 155, 176, 178–180,  
182–184, 189–192, 208, 220, 260  
Prostate cancer  
castration therapy-resistant ..... 259, 260  
heterogeneity ..... 2, 13, 18, 55  
mouse models ..... 29–53, 132–143, 145,  
195–206  
prognosis ..... 154  
progression ..... 30, 31, 82, 84, 117, 118, 132,  
176, 208, 259  
Prostate regeneration ..... 135, 136,  
145, 146  
Proteomics ..... 210, 211

**R**

Radical prostatectomy (rPE) ..... 13, 64, 105, 108, 109,  
154, 242  
Reporter studies ..... 94  
RNA isolation ..... 92, 122, 144

**S**

Scratch assay ..... 71–72  
Slippage ..... 155, 156, 158, 171  
Spheroid cultures ..... 175, 184, 185, 190–191  
Spindle assembly checkpoint (SAC) ..... 154–156, 158, 171  
SRC-1 ..... 260, 261  
Subrenal capsule implantation ..... 14–15

**T**

Taxanes ..... 153–170  
Tissue microarrays  
scoring and analyzing ..... 110, 113, 153  
TMPRSS2 ..... 63, 107, 131–149, 222  
Transcription factors (TFs) ..... 68, 117, 118, 131,  
208, 220, 221, 260  
Transgenic adenocarcinoma of the murine prostate ..... 30  
Transurethral resection of the prostate ..... 13  
Trypsinization assay ..... 214  
Tumor angiogenesis ..... 30, 176, 177  
Tumor invasion ..... 154, 176  
Tumor microenvironment ..... 2, 15, 82, 83, 176,  
178, 195, 238  
Tumor migration ..... 68  
Tumor spheres ..... 63  
Tumor transplantation  
intra-osseous ..... 83  
orthotopic ..... 21, 82, 177  
subcutaneous ..... 82  
systemic ..... 83

**W**

Whole-body optical imaging ..... 81–100